Impact Events
MoreDate | Lead Company | Event | Type | Approval Change | Approval Likelihood |
---|---|---|---|---|---|
5/20/24 | Esperion Therapeutics (ESPR) | Nexletol for Dyslipidemia / Hypercholesterolemia | Subscribers Only | Subscribers Only | Subscribers Only |
5/19/24 | Chiesi Farmaceutici | GB002 for Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension (PH) | Subscribers Only | Subscribers Only | Subscribers Only |
5/17/24 | Viatris (VTRS) | Pretomanid for Tuberculosis | Subscribers Only | Subscribers Only | Subscribers Only |
5/16/24 | Eli Lilly (LLY) | Efsitora alfa for Diabetes Mellitus, Type II | Subscribers Only | Subscribers Only | Subscribers Only |
5/13/24 | Novo Nordisk (NVO) | Mim8 for Hemophilia A | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
MoreExpected Date Range | Lead Company | Drug | Expected Catalyst |
---|---|---|---|
03/19/24 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
04/09/24 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
04/15/24 | Subscribers Only | Subscribers Only | Partnership - Acquisition Completion |
04/15/24 | Subscribers Only | Subscribers Only | Partnership - Acquisition Completion |
04/18/24 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |